Journal profile · Psychiatry
Psychopharmakotherapie
ISSN 0944-6877 · Wissenschaftliche Verlagsgesellschaft Stuttgart · GERMANY · Quarterly · Founded 1994
FollowGet an email when its zone, impact factor or warning status changes
Psychopharmakotherapie: subscription journal; community-reported acceptance: easy; 36 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Psychopharmakotherapie is published by Wissenschaftliche Verlagsgesellschaft Stuttgart. By OpenAlex counts of its recent articles, its largest topics are Treatment of Major Depression, Schizophrenia research and treatment and Substance Abuse Treatment and Outcomes, together about 33.1% of its articles. Its main subfields are Psychiatry and Mental health and Pharmacology. (generated from OpenAlex topic counts and CAS ranking data)
„Psychopharmakotherapie“ (PPT) is the only German-language journal with a single focus on the pharmacotherapy of psychiatric and neurologic diseases, especially under the aspects pharmacology, evaluation in clinical studies, postmarketing surveillance, drug risks, pharmacoeconomics, and practical experiences . Its aim is to inform German-speaking psychiatrists and neurologists (clinicians as well as practitioners) on best practice and current developments in this field. PPT provides reviews, original (= research) papers, editorials, commentaries, case reports, and short reports on high-level publications and congress presentations. Reviews, original papers, commentaries, and case reports are subject to peer review.
Source: LetPub
Research area (LetPub): Psychiatry
Main research topics OpenAlex counts of recent articles; shares are approximate
- Treatment of Major DepressionMedicine14.4%
- Schizophrenia research and treatmentMedicine12.7%
- Substance Abuse Treatment and OutcomesMedicine5.9%
- Pharmaceutical Practices and Patient OutcomesMedicine5.1%
- Electroconvulsive Therapy StudiesMedicine5.1%
- Psychedelics and Drug StudiesPsychology5.1%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics4.2%
- Migraine and Headache StudiesMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pharmacology (medical) | Q4 | 264/278 | 5th |
| Psychiatry and Mental Health | Q4 | 557/580 | 4th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
- CiteScore 2026-06
- 0.2LetPub ·
- SJR 2026-06
- 0.12LetPub ·
- SNIP 2026-06
- 0.05LetPub ·
- h-index
- 11LetPub ·
- h-index
- 3OpenAlex ·
- i10-index
- 1OpenAlex ·
- 2-year mean citedness
- 0.15OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
- Articles per year
- 35LetPub ·
Articles by year OpenAlex count · 67 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 18 | 3 | 8 |
| 2025 | 36 | 17 | 0 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average acceptance (community reports)
- EasyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Before you submit
Three checks before submitting to Psychopharmakotherapie
- 1ScopeRecent output centres on Treatment of Major Depression, Schizophrenia research and treatment.Check scope
- 2Article type and formatPrepare text, figures and references as the author guidelines ask.
- 3English languagePolish grammar and academic style before you submit: it lowers the risk of rejection for language and improves your chances of acceptance.
The checks are built from this page's data.
Profile
Publication details and official links
- Publisher
- Wissenschaftliche Verlagsgesellschaft Stuttgart
- Country or region
- GERMANY
- Frequency
- Quarterly
- Founded
- 1994
- ISSN
- 0944-6877
- Official links
- Journal homepage ↗LetPub
FAQ
Frequently asked questions about Psychopharmakotherapie
Which databases index Psychopharmakotherapie?
According to LetPub and DOAJ records, Psychopharmakotherapie is indexed in Scopus.
Is Psychopharmakotherapie open access, and what is the APC?
Psychopharmakotherapie is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .